MedTrace Logo

Melatonin Receptor Agonist and Peripheral Biological Markers

NCT03432091 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2022-10-10

No results posted yet for this study

Summary

People who have insomnia typically co-occur with mental disorders, especially anxiety and depression. It has been documented that the melatonin phase in the depressed patients was reached with a delay. Melatonin plays a crucial role in regulation of circadian-clock-related gene expression.

Conditions

Interventions

DRUG

melatonin

Ramelteon RMT (RMT, Rozerem®), a novel MT1 and MT2 agonist, has been approved for treatment of insomnia, and provides a strong phase shift signal to the circadian timing system. Melatonin receptor agonists have recently become available for treatment of sleep and psychiatric disorders

Sponsors & Collaborators

  • National Science and Technology Council, Taiwan

    lead OTHER_GOV

Principal Investigators

  • Kuan-Pin Su, MD PhD · China Medical University Hospital

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-11
Primary Completion
2018-12-31
Completion
2019-07-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03432091 on ClinicalTrials.gov